GlassScriptPhysician profile
Jose Piriz
NPI 1770565889
$3,017.54
in general payments reported to CMS, 2019-2025
21 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $121 · 2021: $597 · 2022: $837 · 2023: $489 · 2024: $324 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $4.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.78 |
| Education | $4.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $427.72 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $309.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $284.56 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $277.58 | 2019-2025 | Brilinta, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $271.02 | 2019-2025 | Camzyos |
| Amgen INC. | $258.16 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $232.30 | 2021-2023 | Verquvo |
| Pfizer INC. | $215.88 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $172.13 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $130.99 | 2023-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.01 | 2021-2025 | Jardiance |
| Bard Peripheral Vascular, INC. | $85.43 | 2019 | |
| Amarin Pharma, INC. | $75.61 | 2019-2021 | |
| Abbott Laboratories | $33.53 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $32.57 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $21.88 | 2023 | |
| Phathom Pharmaceuticals, INC. | $21.35 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $20.97 | 2023 | Keveyis |
| Lilly USA, LLC | $18.81 | 2023 | Mounjaro |
| Abbvie INC. | $15.49 | 2022 | |
| Kestra Medical Technology Services, INC. | $14.91 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Piriz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.